A new approach for centerline extraction in handwritten strokes: an application to the constitution of a code book

International audienceWe present in this paper a new method of analysis and decomposition of handwritten documents into glyphs (graphemes) and their associated code book. The different techniques that are involved in this paper are inspired by image processing methods in a large sense and mathematical models implying graph coloring. Our approaches provide firstly a rapid and detailed characterization of handwritten shapes based on dynamic tracking of the handwriting (curvature, thickness, direction, etc.) and also a very efficient analysis method for the categorization of basic shapes (graphemes). The tools that we have produced enable paleographers to study quickly and more accurately a large volume of manuscripts and to extract a large number of characteristics that are specific to an individual or an era

Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS--A Novel Therapeutic Opportunity.

IdeS is a streptococcal protease that cleaves IgG antibodies into F(ab’)2 and Fc fragments with a unique degree of specificity, thereby providing a novel treatment opportunity of IgG-driven autoimmune conditions and antibody mediated transplant rejection. Here we report the results from a first in man, double blinded and randomized study with single ascending doses of IdeS in healthy, male subjects. Twenty healthy subjects were given intravenous single ascending doses of IdeS. With impressive efficacy IdeS cleaved the entire plasma IgG-pool only minutes after dosing. IgG reached nadir 6-24 hours after dosing and then slowly recovered. The half-life of IdeS was 4.9 (±2.8) hours at 0.24 mg/kg with the main fraction eliminated during 24 hours. Already two hours after IdeS-dosing, the phagocytic capacity of IgG/IgG-fragments was reduced to background levels. Importantly, IdeS has the capacity to inactivate Fc-mediated effector function in vivo, was considered safe with no serious adverse events, and without dose limiting toxicity in this study. The complete, rapid, but temporary removal of IgG provides a new potent therapeutic opportunity in IgG-mediated pathogenic conditions.ClinicalTrials.gov NCT01802697